Top Biotechnology Startups in 2027

H1 was built by scientists for scientists. We empower stakeholders at healthcare and life science companies to make smarter scientific decisions by providing access to critical data through an intuitive interface. Working with some of the largest and most influential global life science organizations, H1 provides insight into thought leaders, scholarly content, academics, and healthcare professionals with much more on the way.

Relay Therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments.

TrialSpark is transforming the way new medical treatments are brought to market. We’re a technology company that runs end-to-end clinical trials through a network of our own TrialSpark-operated trial sites, making the entire lifecycle of clinical trials more efficient, accessible, and patient-centric. We're growing quickly and would love to have you join us!

Q Bio is revolutionizing primary care with the first clinical digital twin platform, powered by breakthrough whole-body scanning technology, that highlights the most important changes in a person’s physiology for sharing with physicians and specialists anywhere in the world. The company was founded in 2015 and is headquartered in San Carlos, California. Q Bio was founded by Jeffrey Kaditz, serial entrepreneur and Founder of Affirm, Dr Michael Snyder, Chair of Genetics and Director of Personalized Medicine and Stanford University, and Dr Garry Choy, physician, radiologist, and former Chief Medical Information Officer at Mass General Hospital. We are fortunate to be backed by some of the best venture groups in the world including: A16Z, Khosla Ventures, Founders Fund, SciFi VC, and Kevin Durant.

Synthego’s vision is to turn biology into an information science, with the ultimate goal of dramatically extending the healthy human lifespan. Synthego builds advanced bioinformatics and automated hardware platforms to create next-generation molecular biology tools, starting with full-stack genome engineering. These world-class tools accelerate basic scientific discovery, critical disease cures and novel synthetic biology applications to improve and prolong life.

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with [Amgen](endpts.com/amgen-lines-up-new-ai-biotech-partner-in-postera), [Pfizer](endpts.com/a-new-ai-startup-has-emerged-and-pfizer-likes-what-it-sees) and the [NIH](endpts.com/nih-grants-over-500m-to-create-antivirals-for-future-pandemics). PostEra also launched and led the world's largest open-science drug discovery effort; [COVID Moonshot](postera.ai/moonshot).

We’re a growing company. Everything we do, we do to help people grow into the best version of themselves. As the pioneers of hair wellness, we create natural, clinically effective formulas for hair growth and provide support for people at every step of their hair journey. Our multi-factorial approach targets the root causes of hair thinning using a patented blend of medical-grade botanicals—and is recommended by over 3,000 physicians and hair professionals for trusted, reliable results. We never settle, and are continuously challenging existing treatments and methodologies to advance the frontier of hair science. As we help our customers grow, we grow too—by embracing individuality and differences, leading by example, and empowering ourselves and others with our passion for wellness and innovation. Keep growing. It’s our mantra. Our commitment to helping anybody and everybody committed to realizing their own potential to grow.

Synonym is a financing and development platform for essential biomanufacturing infrastructure - we’re building production capacity for synthetic biology companies and creating a new asset class for investors. We provide synbio companies with flexible capacity for microbial fermentation.  We build new biomanufacturing facilities, offering synbio companies access to dedicated, scalable capacity for minimal upfront capital investment. We accelerate project timelines and minimize internal complexity by handling facility development activities, from site selection through commissioning. We provide capital markets partners with curated access to biomanufacturing infrastructure investments, an emerging asset class and we manage these investments on behalf of investors, with an emphasis on risk management and maximizing returns.

In our highly automated, fast-paced labs, manual pipetting is a thing of the past. We build open-source lab robotics, cutting edge diagnostic tests, and the world’s first full-cycle solutions for no-code AI and genome-scale synthetic biology. Our teams are dedicated to working smarter by developing a platform that integrates robotics, software, assay development, and lab operations to supercharge the pace of innovation in life sciences. Through our continuous R&D efforts, we are extending this platform for the detection of diverse human pathogens, providing unprecedented accessibility for clinically actionable information to improve human health. To be a world-class innovator at the intersection of science and technology, we strive to be a place where diverse teams can come together to do their finest work. Ideally, people who are passionate, collaborative, and who truly want to work together to make a difference. The sky's the limit when it comes to the positive impacts that our work can have on humanity, and it all starts with nurturing the development of our own employees. We provide excellent benefits, competitive compensation, equity packages, and endless opportunities for growth. If you are looking for your next exciting opportunity, come join us! Benefits -Comprehensive Medical, Dental and Vision insurance for employees and their families -Paid Vacation and Sick Leave -Generous Stock options -401k with 4% company match -Long-term and short-term Life & Disability insurance -And much more! *Opentrons is an equal opportunity employer and does not discriminate in employment on the basis of race, color, religion, sex (including pregnancy and gender identity), national origin, political affiliation, sexual orientation, marital status, disability, genetic information, age, membership in an employee organization, retaliation, parental status, military service, or other non-merit factor.

We push the boundaries of molecular diagnostics through quantitative technologies. BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible for all. Our patent-pending QCT molecular counter platform is the only technology platform that can accurately count the DNA molecules to the single-count level.